Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Colburn Website

Nancy H. Colburn, Ph.D.

Selected Publications
1)  Duan D, Sigano DM, Kelley JA, Lai CC, Lewin NE, Kedei N, Peach ML, Lee J, Abeyweera TP, Rotenberg SA, Kim H, Kim YH, Kazzouli SE, Chung JU, Young HA, Young MR, Baker A, Colburn NH, Haimovitz-Friedman A, Truman JP, Parrish DA, Deschamps JR, Perry NA, Surawski RJ, Blumberg PM, Marquez VE.
Conformationally Constrained Analogues of Diacylglycerol. 29. Cells Sort Diacylglycerol-Lactone Chemical Zip Codes to Produce Diverse and Selective Biological Activities.
J. Med. Chem. 2008. [Journal]
2)  Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu X, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH.
Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.
Cancer Prevention Research. 1(1): 45-55, 2008. [Journal]
3)  Colburn NH, Kensler TW.
Targeting transcription factors for cancer prevention - the case of Nrf2.
Cancer Prevention Research. 1(3): 153-155, 2008. [Journal]
4)  Guo D, Han J, Adam BL, Colburn NH, Wang MH, Dong Z, Eizirik DL, She JX, Wang CY.
Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress.
Biochem. Biophys. Res. Commun. 337: 1308-18, 2005. [Journal]
5)  Hu J, Haseebuddin M, Young M, Colburn NH.
Suppression of p65 phosphorylation coincides with inhibition of IkappaBalpha polyubiquitination and degradation.
Mol. Carcinog. 44: 274-84, 2005. [Journal]
6)  Bobe G, Barrett KG, Mentor-Marcel RA, Saffiotti U, Young MR, Colburn NH, Albert PS, Bennink MR, Lanza E.
Dietary cooked navy beans and their fractions attenuate colon carcinogenesis in azoxymethane-induced ob/ob mice.
Nutrition and cancer. 60: 373-81, 2008. [Journal]
7)  Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H.
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.
Oncogene. 27: 2128-36, 2008. [Journal]
8)  Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y.
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene.
Oncogene. 27: 4373-9, 2008. [Journal]
9)  Nieves-Alicea R, Colburn NH, Simeone A, Tari AM.
Programmed Cell Death 4 inhibits breast cancer cell invasion by increasing Tissue Inhibitor of Metalloproteinases-2 expression.
Breast Cancer Res. Treat. Epub ahead of print, 2008. [Journal]
10)  Song C, Xiao Z, Nagashima K, Li CC, Lockett SJ, Dai RM, Cho EH, Conrads TP, Veenstra TD, Colburn NH, Wang Q, Wang JM.
The heavy metal cadmium induces valosin-containing protein (VCP)-mediated aggresome formation.
Toxicol. Appl. Pharmacol. 228: 351-63, 2008. [Journal]
11)  Schmid T, Jansen AP, Baker AR, Hegamyer G, Hagan JP, Colburn NH.
Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion.
Cancer Res. 68: 1254-60, 2008. [Journal]
12)  Ruocco KM, Goncharova EI, Young MR, Colburn NH, McMahon JB, Henrich CJ.
A high-throughput cell-based assay to identify specific inhibitors of transcription factor AP-1.
J Biomol Screen. 12: 133-9, 2007. [Journal]
13)  Hwang SK, Jin H, Kwon JT, Chang SH, Kim TH, Cho CS, Lee KH, Young MR, Colburn NH, Beck GR, Yang HS, Cho MH.
Aerosol-delivered programmed cell death 4 enhanced apoptosis, controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 luciferase reporter mice.
Gene Ther. 14: 1353-61, 2007. [Journal]
14)  Matthews CP, Colburn NH, Young MR.
AP-1 a target for cancer prevention.
Curr Cancer Drug Targets. 7: 317-24, 2007. [Journal]
15)  Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR, Young MR, Colburn NH.
Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.
Cancer Res. 67: 2430-8, 2007. [Journal]
16)  Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH, Allgayer H.
Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer.
Cancer. 110: 1697-707, 2007. [Journal]
17)  Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S, Berestein GL.
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Mol. Cancer Res. 5: 95-108, 2007. [Journal]
18)  LaRonde-LeBlanc N, Santhanam AN, Baker AR, Wlodawer A, Colburn NH.
Structural basis for inhibition of translation by the tumor suppressor Pdcd4.
Mol. Cell. Biol. 27: 147-56, 2007. [Journal]
19)  Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H.
Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors.
Oncogene. 26: 4550-62, 2007. [Journal]
20)  Jin H, Kim TH, Hwang SK, Chang SH, Kim HW, Anderson HK, Lee HW, Lee KH, Colburn NH, Yang HS, Cho MH, Cho CS.
Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice.
Mol. Cancer Ther. 5: 1041-9, 2006. [Journal]
21)  Chang S, Yu KN, Lee Y, An G, Beck Jr GR, Colburn NH, Lee K, Cho M.
Elevated Inorganic Phosphate Stimulates AKT-ERK1/2-Mnk1 Signaling in Human Lung Cells.
Am J Respir Cell Mol Biol. 35: 528-39, 2006. Full Text Article. [Journal]
22)  Young MR, Colburn NH.
Fra-1 a target for cancer prevention or intervention.
Gene. 379: 1-11, 2006. [Journal]
23)  Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M.
S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth.
Science. 314: 467-71, 2006. [Journal]
24)  Shen Q, Zhang Y, Uray IP, Hill JL, Kim H, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH.
The AP-1 transcription factor regulates postnatal mammary gland development.
Dev Biol. 295: 589-603, 2006. Full Text Article. [Journal]
25)  Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, Tan TH, Colburn NH.
Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.
Mol. Cell. Biol. 26: 1297-306, 2006. [Journal]
26)  Weber TJ, Siegel RW, Markillie LM, Chrisler WB, Lei XC, Colburn NH.
A paracrine signal mediates the cell transformation response to low dose gamma radiation in JB6 cells.
Mol Carcinog. 43: 31-7, 2005. [Journal]
27)  Jansen AP, Camalier CE, Colburn NH.
Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.
Cancer Res. 65: 6034-41, 2005. [Journal]
28)  Hu J, Colburn NH.
Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
Mol Cancer Res. 3: 100-9, 2005. [Journal]
29)  Zakowicz H, Yang HS, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH.
Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI.
RNA. 11: 261-74, 2005. [Journal]
30)  Zhao Y, Chaiswing L, Velez JM, Batinic-Haberle I, Colburn NH, Oberley TD, St Clair DK.
p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase.
Cancer Res. 65: 3745-50, 2005. [Journal]
31)  Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH.
A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A.
Mol Cell Biol. 24: 3894-906, 2004. [Journal]
32)  Hou DX, Kai K, Li JJ, Lin S, Terahara N, Wakamatsu M, Fujii M, Young MR, Colburn N.
Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms.
Carcinogenesis. 25: 29-36, 2004. [Journal]
33)  Jansen AP, Camalier CE, Stark C, Colburn NH.
Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity.
Mol Cancer Ther. 3: 103-10, 2004. [Journal]
34)  Dhar A, Hu J, Reeves R, Resar LM, Colburn NH.
Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
Oncogene. 23: 4466-76, 2004. [Journal]
35)  Hu J, Nakano H, Sakurai H, Colburn NH.
Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-{kappa}B activation and transformation in resistant JB6 cells.
Carcinogenesis. 25: 1991-2003, 2004. [Journal]
36)  Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT.
Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model.
Mol Cancer Res. 1: 848-54, 2003. [Journal]
37)  Dhar A, Brindley JM, Stark C, Citro ML, Keefer LK, Colburn NH.
Nitric oxide does not mediate but inhibits transformation and tumor phenotype.
Mol Cancer Ther. 2: 1285-93, 2003. [Journal]
38)  Yang HS, Knies JL, Stark C, Colburn NH.
Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation.
Oncogene. 22: 3712-20, 2003. [Journal]
39)  Young MR, Yang HS, Colburn NH.
Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4.
Trends Mol Med. 9: 36-41, 2003. [Journal]
40)  Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH.
The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.
Mol Cell Biol. 23: 26-37, 2003. [Journal]
41)  Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH.
The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.
Mol Cell Biol. 23: 26-37, 2003. [Journal]
42)  Thompson EJ, MacGowan J, Young MR, Colburn N, Bowden GT.
A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion.
Cancer Res. 62: 3044-7, 2002. [Journal]
43)  Shimamura T, Hsu TC, Colburn NH, Bejcek BE.
Activation of NF-kappaB is required for PDGF-B chain to transform NIH3T3 cells.
Exp Cell Res. 274: 157-67, 2002. [Journal]
44)  Suzukawa K, Colburn NH.
AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
Oncogene. 21: 2181-90, 2002. [Journal]
45)  Suzukawa K, Weber TJ, Colburn NH.
AP-1, NF-kappa-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model.
Environ Health Perspect. 110: 865-70, 2002. [Journal]
46)  Willis DB, Colburn NH.
Molecular targets for cancer prevention: a meeting review of the third American Cancer Society-Schilling Research Conference.
Cancer Epidemiol Biomarkers Prev. 11: 972-8, 2002. [Journal]
47)  Young MR, Farrell L, Lambert P, Awasthi P, Colburn NH.
Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun.
Mol Carcinog. 34: 72-7, 2002. [Journal]
48)  Yu CY, Wang L, Khaletskiy A, Farrar WL, Larner A, Colburn NH, Li JJ.
STAT3 activation is required for interleukin-6 induced transformation in tumor-promotion sensitive mouse skin epithelial cells.
Oncogene. 21: 3949-60, 2002. [Journal]
49)  Dhar A, Young MR, Colburn NH.
The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive.
Mol Cell Biochem. 234-235: 185-93, 2002. [Journal]
50)  Young MR, Nair R, Bucheimer N, Tulsian P, Brown N, Chapp C, Hsu TC, Colburn NH.
Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently.
Mol Cell Biol. 22: 587-98, 2002. [Journal]
51)  Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL, Colburn NH.
A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation.
Oncogene. 20: 669-76, 2001. [Journal]
52)  Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH.
Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation.
Cancer Res. 61: 4160-8, 2001. [Journal]
53)  Hsu TC, Young MR, Cmarik J, Colburn NH.
Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis.
Free Radic Biol Med. 28: 1338-48, 2000. [Journal]
54)  Cmarik JL, Hegamyer G, Gerrard B, Dean M, Colburn NH.
cDNA cloning and mapping of mouse pleckstrin (Plek), a gene upregulated in transformation-resistant cells.
Genomics. 66: 204-12, 2000. [Journal]
55)  Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S, Colburn NH.
Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation.
Proc Natl Acad Sci U S A. 96: 14037-42, 1999. [Journal]
56)  Young MR, Li JJ, Rincón M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn N.
Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion.
Proc Natl Acad Sci U S A. 96: 9827-32, 1999. [Journal]

This page was last updated on 10/1/2008.